Silexion’s proprietary LODER™ platform enables targeted oncogene silencing, using siRNA to block the production of oncogenic proteins. This approach differs from small molecule KRAS inhibitors targeting already-produced oncogenic proteins. The localized delivery system bypasses tumor barriers, ensuring higher treatment concentrations within the tumor while minimizing systemic side effects.
SIL-204, Silexion’s improved siRNA formulation, targets a broader range of KRAS mutations, addressing a limitation of current KRAS inhibitors. It is expected to enter Phase 2/3 clinical trials in 2025-2026.
Pancreatic cancer is a particularly challenging disease due to late detection, aggressive growth, a dense tumor microenvironment, genetic complexity, and resistance to chemotherapy.
Silexion’s LODER™ and SIL-204 technologies are designed to overcome these challenges. Silexion aims to improve treatment outcomes for pancreatic cancer patients by directly targeting KRAS mutations and delivering treatment locally.
The increasing prevalence of KRAS-driven cancers and the growing M&A activity in the precision oncology space further highlight the potential for Silexion Therapeutics. As a recently de-SPACed company, it represents an opportunity for investors interested in the rapidly growing field of targeted cancer treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
